Business
Publication of Report & Accounts and Notice of AGM
Publication of Report & Accounts and Notice of AGM.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 5660H ValiRx PLC 31 May 2011 \n \n\n31 May 2011\n \n \nValiRx Plc\n(\"ValiRx\" or \"the Company\")\n \nPublication of Report & Accounts and Notice of AGM\n \n \n \n \nValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, gives notice that its Report and Accounts for the year ended 31 December 2010 have been posted to shareholders today together with a notice of its Annual General Meeting (\"AGM\") to be held at 10:00 a.m. on 23 June 2011 at the offices of Nabarro LLP at Lacon House, 84 Theobald's Road, London WC1X 8RW.\n \nCopies of the 2010 Report & Accounts and the notice of AGM are also available on ValiRx's website at www.valirx.com. \n \n \n \nFor more information, please contact:\n \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nDr. Satu Vainikka\n\n\n\n\n\n\n\nwww.valirx.com\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP \n\n\n Tel: +44 (0) 20 7148 7900\n\n\n\n\nNominated Adviser\n\n\n\n\n\n\n\nLiam Murray / Avi Robinson\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nHybridan LLP \n\n\n Tel: +44 (0) 207 947 4350\n\n\n\n\nBroker \n\n\n\n\n\n\n\nClaire Noyce\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeckwater PR\n\n\n\n\n\n\n\nTarquin Edwards\n\n\nTel: +44 (0)7879 458 364\n\n\n\n\n\n\n\[email protected]\n\n\n\n\n \n \nNotes for Editors\n \nValiRx Plc\nValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.\n \nThe Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the great...